New Zealand markets closed
  • NZX 50

    12,185.65
    +57.44 (+0.47%)
     
  • NZD/USD

    0.6689
    -0.0002 (-0.03%)
     
  • NZD/EUR

    0.5914
    +0.0001 (+0.02%)
     
  • ALL ORDS

    7,248.10
    -193.40 (-2.60%)
     
  • ASX 200

    6,961.60
    -177.90 (-2.49%)
     
  • OIL

    85.25
    -0.35 (-0.41%)
     
  • GOLD

    1,847.50
    -5.00 (-0.27%)
     
  • NASDAQ

    14,149.12
    -360.46 (-2.48%)
     
  • FTSE

    7,371.46
    +74.31 (+1.02%)
     
  • Dow Jones

    34,297.73
    -66.77 (-0.19%)
     
  • DAX

    15,123.87
    +112.74 (+0.75%)
     
  • Hang Seng

    24,224.32
    -19.29 (-0.08%)
     
  • NIKKEI 225

    27,069.83
    -61.51 (-0.23%)
     
  • NZD/JPY

    76.1470
    +0.0270 (+0.04%)
     

Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

·1-min read

SAN FRANCISCO, November 18, 2021--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, Chief Financial Officer, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021.

A webcast of the pre-recorded corporate presentation will be available on-demand starting November 22, 2021 at 10:00am EST on the events section of the company’s investor relations website. An archived copy of the webcast will be available on the company’s website for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006126/en/

Contacts

Media
Will Zasadny
Canale Communications
(619) 961-8848
will.zasadny@canalecomm.com
media@sprucebiosciences.com

Investors
Xuan Yang
Solebury Trout
(415) 971-9412
xyang@soleburytrout.com
investors@sprucebiosciences.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting